Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review
Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)
DOI: 10.1002/edm2.70338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 16.09.2026. Verfasst von Hiba Bawadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Nutrition, College of Health Sciences, QU-HEALTH, Qatar University, Doha, Qatar. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Liraglutide. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges. Incretin‐based therapies, including the GLP‐1 receptor agonists semaglutide and liraglutide, and the dual GIP/GLP‐1 receptor agonist tirzepatide, are increasingly used to address hyperglycaemia and obesity, and have been evaluated for both cardiometabolic risk markers and selected cardiovascular and renal outcomes.
Objective
This review summarizes and contrasts the pharmacology of semaglutide, liraglutide and tirzepatide, distinguishing between surrogate cardiometabolic risk markers (e.g., glycaemic control, body weight and lipid parameters) and confirmed clinical outcomes, including major adverse cardiovascular events (MACE) and renal endpoints.
Methods
Recent data were synthesized from pivotal randomized clinical trial programs, SUSTAIN and PIONEER (semaglutide), LEADER (liraglutide) and SURPASS and SURMOUNT (tirzepatide), as well as meta‐analyses, post hoc analyses and observational studies addressing mechanistic and long‐term cardiometabolic outcomes.
Results
All three agents improved HbA1c, weight and cardiometabolic outcomes, with tirzepatide generally showing greater reductions across clinical trials. Semaglutide and liraglutide consistently improved BMI, lipid profile and cardiovascular risk, while tirzepatide shows promise pending CVOT data. Renal outcomes were favourable across the class, though results varied by baseline characteristics and trial design.
Conclusion
Semaglutide, liraglutide and tirzepatide are key therapies for type 2 diabetes and cardiometabolic disease. Tirzepatide's dual activity may enhance metabolic and lipid outcomes, while semaglutide and liraglutide have strong evidence for cardiovascular and renal safety. However, comparisons are based on indirect evidence and should be interpreted cautiously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Nutrition, College of Health Sciences, QU-HEALTH, Qatar University, Doha, Qatar.
- Clinical Affairs Department, QU-HEALTH, Qatar University, Doha, Qatar.
- Department of Biomedical Sciences, College of Health Sciences, QU-HEALTH, Qatar University, Doha, Qatar.
- Nottingham University Hospitals NHS Trust, Nottingham, UK.
- Biomedical Research Center, QU-HEALTH, Qatar University, Doha, Qatar.
ORCID-Profile: Hiba Bawadi, Haya Abuhijleh, Mamon Nofal, Zain Z Zakaria, Maha Al-Asmakh
Zitieren
APA
Bawadi, H., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al-Asmakh, M. (2026). Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70338
Vancouver
Bawadi H, Abuhijleh H, Nofal M, Zakaria ZZ, Al-Asmakh M. Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70338
BibTeX
@article{Bawadi2026,
author = {Bawadi, Hiba and Abuhijleh, Haya and Nofal, Mamon and Zakaria, Zain Z and Al-Asmakh, Maha},
title = {Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/edm2.70338}
}
EUVIMED